HKPD vs HCWB vs IMVT vs ATXG

For growth investors, Hong Kong Pharma Digital Technology Holdings Limited (HKPD) is the stronger pick with 21.

7% revenue growth year-over-year, versus -97. 9% for HCW Biologics Inc. (HCWB). Analysts rate Immunovant, Inc. (IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -99. 9% for HCW Biologics Inc. (HCWB). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus ATXG's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Immunovant, Inc.

(IMVT) is the lower-risk stock at 1. 37β versus Hong Kong Pharma Digital Technology Holdings Limited's 1. 66β — meaning HKPD is approximately 21% more volatile than IMVT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for HCW Biologics Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hong Kong Pharma Digital Technology Holdings Limited (HKPD) is pulling ahead at 21.

7% versus -97. 9% for HCW Biologics Inc. (HCWB). On earnings-per-share growth, the picture is similar: Addentax Group Corp. grew EPS -19. 7% year-over-year, compared to -1280. 5% for HCW Biologics Inc.. Over a 3-year CAGR, ATXG leads at -30. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Immunovant, Inc.

(IMVT) is the more profitable company, earning 0. 0% net margin versus -146. 8% for HCW Biologics Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HKPD leads at 0. 7% versus -207. 6% for HCWB. At the gross margin level — before operating expenses — HCWB leads at 20. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Immunovant, Inc.

(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+173. 6% 10Y return). Hong Kong Pharma Digital Technology Holdings Limited (HKPD) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMVT: +173. 6%, HKPD: -77. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HKPD (Industrials) and HCWB (Healthcare) and IMVT (Healthcare) and ATXG (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HKPD is a small-cap high-growth stock; HCWB is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ATXG is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.